-
-
-
-
-
-
-
Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer
-
-
-
-
-
-
-
Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer
-
-
-
-
-
-
-
Pfizer faces challenging years on fading COVID sales, margin pressure
-
-
-
-
-
-
-
Pfizer Completes Acquisition of Metsera
-
-
-
-
-
-
-
Pfizer raises and narrows full-year earnings guidance
-
-
-
-
-
-
-
Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk
-
-
-
-
-
-
-
Novo Nodrisk stock dips on aggressive odder to buy Metsera, 'reckless' says Pfizer
-
1,122,779 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

